Publications

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander 1, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert, Ora Rosengarten, Mariana Steiner, Niklas Loman, Karin Bowen, Anitra Fielding, Susan M Domchek
J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.
https://pubmed.ncbi.nlm.nih.gov/25366685/
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, M.D., Nicoletta Colombo, M.D., Giovanni Scambia, M.D., Byoung-Gie Kim, M.D., Ph.D., Ana Oaknin, M.D., Ph.D., Michael Friedlander, M.D., Alla Lisyanskaya, M.D., Anne Floquet, M.D., maintenance olaparib in patients with newly diagnosed advanced ovarian cancerAlexandra Leary, M.D., Gabe S. Sonke, M.D., Ph.D., Charlie Gourley, M.D., Ph.D., Susana Banerjee, M.D., Ph.D., et al.
N Engl J Med 2018; 379:2495-2505
https://www.nejm.org/doi/full/10.1056/NEJMoa1810858
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Prof Angeles Alvarez Secord, Melissa A Geller, Prof David Scott Miller, Noelle Cloven, Prof Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Prof Paul DiSilvestro, Prof Amit M Oza, Mihaela Cristea, Prof Jonathan S Berek, John K Chan, Bobbie J Rimel, Prof Daniela E Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A Matulonis, Bradley J Monk
Published: April 01, 2019
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30029-4/fulltext
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín, M.D., Ph.D., Bhavana Pothuri, M.D., Ignace Vergote, M.D., Ph.D., René DePont Christensen, Ph.D., Whitney Graybill, M.D., Mansoor R. Mirza, M.D., Colleen McCormick, M.D., M.P.H., Domenica Lorusso, M.D., Ph.D., Paul Hoskins, M.D., Gilles Freyer, M.D., Klaus Baumann, M.D., Kris Jardon, M.D., et al., for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*
Published: December 19, 2019
N Engl J Med 2019; 381:2391-2402
https://www.nejm.org/doi/full/10.1056/NEJMoa1910962
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-MartínRegina Berger, Keiichi Fujiwara, Ignace VergoteNicoletta Colombo, M.D., Johanna Mäenpää, Frédéric Selle, Jalid Sehouli, et al., for the PAOLA-1 Investigators*
Published: December 19, 2019
N Engl J Med 2019; 381:2416-2428
https://www.nejm.org/doi/full/10.1056/nejmoa1911361
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer.
Kirsten M Timms, Gordon B. Mills, Michael Perry, Alexander Gutin, Jerry Lanchbury, Robert Brown
Published online May 25, 2020.
DOI: 10.1200/JCO.2020.38.15_suppl.1586 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1586-1586.
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1586
Comparison of genomic instability (GI) scores for predicting PARP activity in ovarian cancer
Kirsten M Timms, Gordon B. Mills, Michael Perry, Alexander Gutin, Jerry Lanchbury, Robert Brown
DOI: 10.1200/JCO.2020.38.15_suppl.1586 Journal of Clinical 296 – POSTER SESSION| VOLUME 159, SUPPLEMENT 1, 139-140, OCTOBER 01, 2020
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1586

References

  • Watkins et al. Breast Ca Res (2014) 16:211
  • Yates et al. Annals of Oncology (2014) 25 (suppl_4): iv305-iv326
  • The Cancer Genome Atlas. Nature (2011) 474: 609-615
  • Kristeleit et al. Presented at ESMO 2016 Congress (Abstract 8560)
  • Pennington et al. Clin Cancer Res (2013) 20(3):764-75
  • Kristeleit et al. Presented at European Cancer Congress 2015 (Abstract 2700)
  • Norquist et al. Presented at 2016 SGO Annual Meeting SGO Annual Meeting on Women’s Cancer (Abstract 1)
  • Konstantinopoulos et al. Cancer Discov (2015) 5(11):1-18
  • Abkevich et al. Br J Cancer (2012) 107:1776–1782
  • Popova et al. Cancer Res (2012) 72(21):5454-62
  • Birkbak et al. Cancer Discov (2012) 2(4):366-75
  • Timms et al. Br Ca Res (2014) 16:475-483
  • Hennessy et al. J Clin Oncol (2010) 28:3570-76 The Cancer Genome Atlas. Nature (2012) 490: 61-70
  • Mills et al. Presented at 2016 SGO Annual Meeting SGO Annual Meeting on Women’s Cancer (Abstract 2)

Website Feedback